The secondary objective was to confirm these clinical results using biomarkers previously validated in DCS such as platelet count [24], [25], with a particular attention on the circulating level of IL-6, a relevant marker of systemic inflammation observed in DCS [4], [23]. The gene discussed is IL6; the disease is Dorfman-Chanarin disease.